Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin M Greenberg

Showing results (111-120 of 133) with videos related to

Pageof 14
Sort By:
Nature Medicine|June 28, 2024
AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patientJames J Dowling, Terry Pirovolakis, Keshini Devakandan, et al.
JAMA Neurology|March 27, 2013
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosisBenjamin M Greenberg, Laura Balcer, Peter A Calabresi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 3, 2026
Clinical and radiological outcomes of directed treatment transitions from Gilenya<sup>®</sup> to generic fingolimodMahi A Patel, Tom G Punnen, Kevin S Shan, et al.
Annals of Neurology|January 10, 2026
A Patient-Derived Antibody Ameliorates Disease Severity in a Relapsing Remitting Murine Model of Multiple SclerosisChad Smith, Benjamin M Greenberg, Jack Reynolds, et al.
European Journal of Immunology|September 3, 2010
Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoproteinChristopher T Harp, Sara Ireland, Laurie S Davis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 6, 2020
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG<i>MS</i> studyDouglas L Arnold, Brenda Banwell, Amit Bar-Or, et al.
Archives of Neurology|July 14, 2010
Translational research in neurology and neuroscience 2010: multiple sclerosisOlaf Stüve, Bernd C Kieseier, Bernhard Hemmer, et al.
ASN Neuro|October 23, 2015
A Distinct Class of Antibodies May Be an Indicator of Gray Matter Autoimmunity in Early and Established Relapsing Remitting Multiple Sclerosis PatientsAnn J Ligocki, Jacqueline R Rivas, William H Rounds, et al.
Archives of Neurology|June 11, 2008
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosisChitra Krishnan, Adam I Kaplin, Robert A Brodsky, et al.
Circulation|June 16, 2021
In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA VaccineAlagarraju Muthukumar, Madhusudhanan Narasimhan, Quan-Zhen Li, et al.
Pageof 14

Showing results (111-120 of 133) with videos related to

Sort By:
Pageof 14
Nature Medicine|June 28, 2024
AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patientJames J Dowling, Terry Pirovolakis, Keshini Devakandan, et al.
JAMA Neurology|March 27, 2013
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosisBenjamin M Greenberg, Laura Balcer, Peter A Calabresi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 3, 2026
Clinical and radiological outcomes of directed treatment transitions from Gilenya<sup>®</sup> to generic fingolimodMahi A Patel, Tom G Punnen, Kevin S Shan, et al.
Annals of Neurology|January 10, 2026
A Patient-Derived Antibody Ameliorates Disease Severity in a Relapsing Remitting Murine Model of Multiple SclerosisChad Smith, Benjamin M Greenberg, Jack Reynolds, et al.
European Journal of Immunology|September 3, 2010
Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoproteinChristopher T Harp, Sara Ireland, Laurie S Davis, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 6, 2020
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG<i>MS</i> studyDouglas L Arnold, Brenda Banwell, Amit Bar-Or, et al.
Archives of Neurology|July 14, 2010
Translational research in neurology and neuroscience 2010: multiple sclerosisOlaf Stüve, Bernd C Kieseier, Bernhard Hemmer, et al.
ASN Neuro|October 23, 2015
A Distinct Class of Antibodies May Be an Indicator of Gray Matter Autoimmunity in Early and Established Relapsing Remitting Multiple Sclerosis PatientsAnn J Ligocki, Jacqueline R Rivas, William H Rounds, et al.
Archives of Neurology|June 11, 2008
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosisChitra Krishnan, Adam I Kaplin, Robert A Brodsky, et al.
Circulation|June 16, 2021
In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA VaccineAlagarraju Muthukumar, Madhusudhanan Narasimhan, Quan-Zhen Li, et al.
Pageof 14